Skip to content

Evaluation of safety of cosmetic product

The objective of this study is to evaluate the irritation potential of five skin care formulations on healthy human subjects with sensitive skin.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/10/046395
Enrollment
26
Registered
2022-10-12
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Moisturex Syndet bathing bar: The product is rinse off product. 8% w/w solution of the investigational products is prepared in distilled water. 40 microliters of the prepared sample is

Sponsors

Sun Pharmaceutical Industries Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Female and male Asian Indian subjects with phototype III-V. 2 Healthy human subjects (no infectious and evolutive pathology which could make the subject vulnerable and stop the study, no pathology which could interfere with the study, no symptom in the process of an exploratory check-up) 3 Between 18 and 65 years of age. 4 Skin is healthy on the studied anatomic unit (e.g., free of eczema, wounds, inflammatory scar) 5 Subjects representing sensitive skin type (as per the Baumannââ?¬•s questionnaire answered by subjects)

Exclusion criteria

Exclusion criteria: 1 For female: Being pregnant or breastfeeding or having stopped to breastfeed in the past three months 2 Having eczema, psoriasis, lichen planus, vitiligo at the test site of analysis. 3 Having disorder of the healing () at the test site of analysis 4 Having rhinitis, allergic conjunctivitis or rhino sinusitis 5 Having hypersensitivity/ allergy to any cosmetics, perfumes and/or conservatives in cosmetic products, etc. 6 Having an allergy to plaster 7 Having a food allergy 8 Having scar excessive terminal hair or tattoo on studied area 9 Having a cardiovascular pathology (taking a beta blocker treatment) 10 Having immunosuppressive drugs, such as cyclophosphamide, methotrexate, azathioprine, etc. Taking a retinoid-based treatment by general or oral route 11 Taking specific treatment on the back. 12 Having taken an anti-histaminic treatment in the last 2 weeks preceding the start of the study 13 Having miliaria (prickly heat) on the back. 14 Presenting too many naevus on the back 15 Having high pilosity on the back. 16 Refusing to follow the restrictions below during the study: - During the first 24 hours (after patch application), neither cosmetic products nor water must be applied on the back. - Till the follow up period of until T8 days, only use of water is acceptable from the first reading i.e., T2 days (24 hours after the patch removal). - Do not practice an intensive sport activity during the first 24 hours (until the removal of the patches) - Do not expose the back to the sun.

Design outcomes

Primary

MeasureTime frame
Dermatological safety / Irritation potential on skinTimepoint: Baseline,0 hrs,24 hrs and 7 days

Secondary

MeasureTime frame
NilTimepoint: Nil

Countries

India

Contacts

Public ContactDr Mohit Lalvani

MASCOT-SPINCONTROL India Pvt. Ltd.

raji@mascotspincontrol.in02243349191

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026